



Coronavirus Variants
Rapid Response
Network



Réseau de réponse
rapide aux variants
du coronavirus



CoVaRRNet

Public Health Implications of SARS-CoV-2 VOC

UPDATED: JULY 29, 2021

JANET CURRAN, PHD RN, DALHOUSIE UNIVERSITY, PROFESSOR

LEAH BOULOS, MLIS, MARITIME SPOR SUPPORT UNIT, EVIDENCE SYNTHESIS COORDINATOR

MARI SOMERVILLE, PHD, DALHOUSIE UNIVERSITY, POSTDOCTORAL FELLOW

JUSTINE DOL, PHD, DALHOUSIE UNIVERSITY, RESEARCH COORDINATOR

CATIE JOHNSON, DALHOUSIE UNIVERSITY, RESEARCH ASSISTANT

DANIEL CROWTHER, DALHOUSIE UNIVERSITY, RESEARCH ASSISTANT

BEARACH REYNOLDS, MB BCH BAO BA MRCPI, ESI FELLOW, EVIDENCE SYNTHESIS IRELAND

FUNDED BY **COVARR-NET**

Public Health Implications of SARS-CoV-2 VOC

Updated July 29, 2021

Evidence up to July 14, 2021

Introduction

The SARS-CoV-2 virus, responsible for COVID-19, was declared a global pandemic by the World Health Organization (WHO) in Mar 2020.¹ As of July 18, 2021, over 190 million cases of COVID-19 had been reported worldwide and over 4 million people have died as a result of COVID-19 since the start of the pandemic.² Increased numbers of COVID-19 cases are causing significant concerns around identifying optimal vaccination strategies and enforcing appropriate public health measures to manage the spread of the SARS-CoV-2 virus.

As of July 29, 2021, four variants of the original SARS-CoV-2 lineage have been declared variants of concern (VOC) by the WHO, with other variants under ongoing assessment (see Table 1).³ VOC are defined by their increased potential for transmission, presence of genomic mutations, and rapid spread across countries or regions leading to possible decreased effectiveness of public health measures.⁴ The increased transmissibility of VOC has led to surges in COVID-19 incidence and consequently, hospitalizations and mortality.⁵ Therefore, this living systematic review aims to provide a synthesis of current evidence related to VOC in the context of public health measures. This living synthesis builds on a previous rapid scoping review examining the impacts of VOC on public health and health systems conducted by this team.⁶

Table 1. Current variants of concern (VOC)^{3 7}

WHO Name	PANGO LINEAGE	Alternate name	Country first detected in	Earliest samples
Alpha	B.1.1.7	VOC 202012/01	United Kingdom	September 2020
Beta	B.1.351	VOC 202012/02	South Africa	August 2020
Gamma	P.1	VOC 202101/02	Brazil	December 2020
Delta	B.1.617.2	N/A	India	October 2020

Key Points of Interest

- The majority of available evidence is related to the Alpha variant; very little published about the Delta variant
- Speed of vaccine rollout is a key factor in reducing transmission rate and disease burden
- Non-pharmaceutical interventions (NPIs) (e.g., social distancing, masking) alongside vaccine rollout is an essential component of an overall disease management plan
- There is evolving evidence regarding changes in vaccine scheduling related to inter-dose timing and need for third dose of vaccine
- Strict NPIs may lead to overdispersion of highly transmissible variants, leading to their eventual dominance
- Lockdowns should be strict when imposed, yet the most effective length is undetermined
- Adherence to strict NPIs and lockdowns wanes over time, which may impact effectiveness

Categories of evidence included in this report are as follows:

Modifying approach to vaccines: Any studies that reported on changing approaches to vaccinations such as modelling the rollout schedules or impact of NPIs in relation to vaccine schedules. Four sub-categories fell under this category:

- a) Modelling potential vaccination rollout schedules
- b) Evaluating past vaccination rollout schedules
- c) Modelling potential vaccination rollout schedules in the presence of NPIs
- d) Evaluating past vaccination rollout schedules in the presence of NPIs

Infection prevention measures: Any studies that reported on public health measures aimed at preventing the spread of VOC such as mask wearing, hand washing or physical distancing.

Infection control measures: Any studies that reported on public health measures aimed at controlling the spread of VOC such as quarantines, lockdowns, screening or testing strategies.

[Results Tables](#)

The following tables present a summary of evidence in relation to each of the categories described above.

Table 2. Evidence related to modifying approach to vaccination, divided by VOC

*Note: only observational studies were appraised for quality

Category	Alpha (B.1.1.7)	Beta (B.1.351)	Gamma (P.1)	Delta (B.1.617.2)
Modifying approach to vaccination				
Modelling potential vaccination rollout schedules	<ul style="list-style-type: none"> Accelerated vaccine rollout (60doses/day/10,000 pop) would reduce severe health outcomes ⁸ Estimated current vaccine schedule of 1/1000 doses/person/day would need to be quadrupled to control the spread of VOC ⁹ Speed of vaccine rollout is key factor in achieving low IAR and burden of disease ¹⁰⁻¹⁴ Change in inter-dose vaccine period from 21 to 42 days is preferable for vaccine mode of action at the end of infection course, severe epidemic and low vaccine supply rate ¹⁵ Third dose of vaccine is required to eliminate developing mutations and reduce transmission rates ¹⁶ Proactive surveillance and prioritized vaccination can reduce severe illness and mortality in vulnerable groups ¹⁷ 	<ul style="list-style-type: none"> Speed of vaccine rollout is key factor in achieving low IAR and disease burden ¹¹ Third dose of vaccine is required to eliminate developing mutations and reduce transmission rates ¹⁶ 	<ul style="list-style-type: none"> Speed of vaccine rollout is key factor in achieving low IAR and disease burden ¹⁴ Third dose of vaccine is required to eliminate developing mutations and reduce transmission rates ¹⁶ 	<ul style="list-style-type: none"> Speed of vaccine rollout is key factor in achieving low IAR and disease burden ¹⁴ Third dose of vaccine is required to eliminate developing mutations and reduce transmission rates ¹⁶

Evaluating vaccination rollout schedules		N/A	<ul style="list-style-type: none"> Targeted vaccination of 80+ age group associated with decreased mortality compared with younger group ¹⁸ <i>Medium quality evidence</i> 	N/A
Modelling different vaccine schedules in relation to NPIs	<ul style="list-style-type: none"> Advocate for NPIs to remain in place during vaccine roll out until sufficient population immunity ^{19–25} NPIs alongside accelerated vaccine roll out is needed to control outbreak ^{23,26–29} In OECD, countries fully vaccinating 40% of the population would allow for easing of containment policies ³⁰ 	<ul style="list-style-type: none"> Advocate for NPIs to remain in place during vaccine roll out until sufficient population immunity ^{19,20} 		Combination vaccine (accelerated) and NPIs are required to reduce transmission rate ^{25,26,31}
Evaluating different vaccine schedules in relation to NPIs	N/A	N/A	N/A	N/A

Table 3. Evidence related to infection prevention measures, divided by VOC

Category	Alpha (B.1.1.7)	Beta (B.1.351)	Gamma (P.1)	Delta (B.1.617.2)
Infection prevention measures				
Hand washing	<ul style="list-style-type: none"> VOC responds similarly to ethanol and soap as non-VOC ³² 	<ul style="list-style-type: none"> VOC responds similarly to ethanol and soap as non-VOC ³² 	N/A	N/A

Masking	<ul style="list-style-type: none"> Moderately effective masks, when worn consistently correctly by a large portion of the population, are effective at preventing transmission ³³ 	N/A	N/A	N/A
Physical distancing	<ul style="list-style-type: none"> Settings where physical distancing is unlikely (e.g., hair salons; visiting with friends inside the home) present the highest risk of transmission ³⁴ Strong physical distancing measures are critical ³⁵ and may need to be strengthened by 33.7% ³⁶ In daycares, strict contact restrictions like group assignments among children and staff assignments to groups prevent infections ³⁷ <p><i>Appraised studies were of medium to high quality</i></p>	<ul style="list-style-type: none"> Strong physical distancing measures are critical even with a mass vaccination campaign ^{19,38} 	<ul style="list-style-type: none"> Strong physical distancing measures are critical even with a mass vaccination campaign³⁸ 	N/A

Table 4. Evidence related to infection control measures, divided by VOC

Category	Alpha (B.1.1.7)	Beta (B.1.351)	Gamma (P.1)	Delta (B.1.617.2)
Infection control measures				
Testing	<ul style="list-style-type: none"> Testing and routine surveillance of populations at risk are critical ^{39 40} Self-collection and pooling approaches to testing of travellers allows large-scale screening using less human, 	<ul style="list-style-type: none"> Testing and routine surveillance of populations at risk are critical even with a mass vaccination campaign ¹⁹ 	<ul style="list-style-type: none"> Mass saliva analysis is a cheap, easy to collect, and feasible asymptomatic testing strategy to potentially slow variant outbreaks ⁴³ 	<ul style="list-style-type: none"> The optimal testing strategy is weekly testing of the entire unvaccinated population, plus a 10-day isolation requirement for positive cases and

	<p>material and financial resources⁴¹; surveillance of travellers remains important²¹</p> <ul style="list-style-type: none"> • Daily testing for 5 days could circumvent the need for quarantine of travellers⁴² • Pre-flight tests may prevent the majority of transmission from travellers⁴² <p><i>Appraised study of high quality</i></p>			<p>their households^{44,45}</p>
Quarantine (close contacts and travellers)	<ul style="list-style-type: none"> • Alpha cases almost twice as likely to give rise to household clusters compared with wild type cases, highlighting importance of quarantining household contacts^{46,47} • Mandatory quarantine and contact tracing are required^{39,42,48-50} • A 10-day quarantine period may be as effective as a 14-day quarantine period⁴² <p><i>Appraised studies of medium quality</i></p>	<ul style="list-style-type: none"> • Mandatory quarantine and contact tracing are required^{49,50} • Beta may require more extreme quarantine and testing measures⁴⁸ than other variants including Alpha 	<ul style="list-style-type: none"> • Mandatory quarantine may be an effective way to contain Gamma⁵⁰ • Forced prolonged cohabiting may boost viral ability to generate Gamma mutation⁵¹ 	
Isolation (confirmed COVID-19/VOC cases)	<ul style="list-style-type: none"> • Complete isolation of Alpha cases is required to prevent outbreaks; even a small number of infected people dramatically increases the probability of sustained community transmission¹⁰ 	N/A	N/A	<ul style="list-style-type: none"> • To control outbreaks, the optimal testing strategy is weekly testing of the entire unvaccinated population, plus a 10-day isolation requirement for positive cases and their households⁴⁴

<p>Lockdowns</p>	<ul style="list-style-type: none"> • Alpha requires stronger lockdown measures than wild type ^{28,52,53} including increased length ⁵⁴ and stricter regional travel restrictions ⁴⁰ • Shorter, stricter lockdowns may be more effective than longer, moderate lockdowns due to waning adherence ²⁸ 	<p>N/A</p>	<p>N/A</p>	<ul style="list-style-type: none"> • Early public interventions— lockdowns imposed during an ‘optimal time window’— lead to reduced death counts from Delta ⁵⁵
<p>Other/combined NPIs</p>	<ul style="list-style-type: none"> • Strong test-trace-isolate programs could be enough to contain Alpha ²⁶ • In day-cares, NPIs like closures in the event of an outbreak can help contain Alpha ⁵⁶ • Strict NPIs may lead to overdispersion of highly transmissible variants, leading to their eventual dominance ⁵⁷ 	<p>N/A</p>	<ul style="list-style-type: none"> • Strict NPIs are required to contain Gamma ³¹ 	<ul style="list-style-type: none"> • Even modest improvements in a find, test, trace, isolate and support program would control transmission ⁵⁸

Overview of the Evidence

As of July 14, 2021, 51 studies have reported on VOC and public health measures. We include 18 studies from an earlier rapid review and 33 from our updated search on July 14th 2021. The key findings of included studies can be found in tables 2-4 below, while a more detailed summary of each study can be found in the supplementary material tables. The majority of reported evidence was related to Alpha (n=27) with fewer studies reporting on Beta (n=7 studies), Gamma (n=8 studies) and Delta (n=12 studies).

Modifying Approach to Vaccines delivery

- 24^{8-28,30,31} studies reported on vaccine delivery. The majority of modelling studies exploring potential vaccine rollout schedules and made recommendations for accelerated vaccination campaigns. This included studies that modelled vaccine rollout in both the presence and absence of NPIs, such as lockdown measures
- NPIs are recommended to continue in tandem with a vaccine rollout schedule

Infection Prevention Measures

- The one³² study that reported on hand washing and VOC, reported that Alpha and Beta respond similarly to ethanol and soap as wildtype SARS-CoV-2
- The one³³ study that reported on mask wearing and VOC, reported that when worn correctly, masks are effective against Alpha
- Six^{19,34-38} studies reported on VOC and physical distancing measures. All studies recommended imposing strong physical distancing measures in the presence of Alpha, Beta or Gamma

Infection Control Measures

- Nine^{19,21,39-45} studies reported on testing strategies related to VOC. Testing and routine surveillance of populations are critical to containing Alpha and Beta, even in the presence of mass vaccination campaigns. Cheaper approaches to testing are possible for detecting Alpha and Gamma.
- Eight^{39,42,46-51} studies reported on quarantine and VOC. Mandatory quarantine were reported as necessary to contain Alpha and Beta. Alpha and Gamma were identified as giving rise to more household clusters than wildtype, suggesting a need for adequate household quarantine measures.
- Two^{10,44} studies reported on isolation and VOC to contain transmission of the virus. One study was related to Alpha and Gamma respectively. Isolation duration varied across studies.
- Six^{28,40,52-55} studies reported on lockdowns and VOC. All studies reported needing strict lockdown measures to contain Alpha. Some studies recommended longer lockdowns and more restrictive travel restrictions, while one study recommended short, strict lockdowns to mitigate the waning adherence to longer lockdowns.
- Five^{26,31,56-58} studies reported on other NPI infection control measures and VOC. Two studies recommended modest to strong test, trace and isolate strategies as necessary to

control the spread of Alpha and Delta. Three studies recommended employing NPIs in conjunction with vaccine rollout to mitigate the spread of Alpha.

Methods

This living synthesis is building on previous evidence gathered up to May 11, 2021. Searches for this update were run on July 14, 2021 in MEDLINE (Ovid MEDLINE All), Embase (Elsevier Embase.com), the Cochrane Database of Systematic Reviews (CDSR) and Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Wiley), Epistemonikos' L·OVE on COVID-19, and medRxiv and bioRxiv. Titles/abstracts and full text were screened independently by two reviewers. Data were double extracted using a standardized form. Studies were included if they reported on at least one of the VOC and public health measures. Critical appraisal was conducted for case-control, cohort, and cross-sectional studies using the Newcastle-Ottawa Scale (for studies included in previous versions of this report) and the appropriate Joanna Briggs critical appraisal tools for studies newly included in this update. Critical appraisal was not conducted for modelling studies.

List of Abbreviations

COVID-19: coronavirus disease 2019

IAR: Infection attack rate

NPI: non-pharmaceutical intervention/s

VOC: variant/s of concern

WHO: World Health Organization

References

1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Bio-Medica Atenei Parm.* 2020 19;91(1):157–60.
2. WHO. Weekly epidemiological update on COVID-19 - 20 July 2021 [Internet]. [cited 2021 Jul 29]. Available from: <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021>
3. WHO. Tracking SARS-CoV-2 variants [Internet]. 2021 [cited 2021 Jun 7]. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
4. WHO. COVID-19 Weekly epidemiological update - February 25, 2021 [Internet]. 2021 Feb [cited 2021 Mar 12]. Available from: <https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update>
5. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* [Internet].

2021 Apr 9 [cited 2021 Apr 24];372(6538). Available from:
<https://science.sciencemag.org/content/372/6538/eabg3055>

6. Curran J, Dol J, Boulos L, Somerville M, McCulloch H. Public Health and Health Systems Impacts of SARS-CoV-2 Variants of Concern: A Rapid Scoping Review. medRxiv. 2021 May 22;2021.05.20.21257517.
7. Public Health Agency of Canada (PHAC). Emerging Evidence on COVID-19: Living summary of SARS-CoV-2 Variants of Concern, April 28th 2021 version. 2021;
8. Sah P, Vilches TN, Moghadas SM, Fitzpatrick MC, Singer BH, Hotez PJ, et al. Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. EClinicalMedicine [Internet]. 2021 May 1 [cited 2021 May 26];35. Available from: [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(21\)00145-0/abstract](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00145-0/abstract)
9. Tokuda Y, Kuniya T. Japan's Covid mitigation strategy and its epidemic prediction. medRxiv. 2021 May 7;2021.05.06.21256476.
10. Sanz-Leon P, Stevenson NJ, Stuart RM, Abey Suriya RG, Pang JC, Lambert SB, et al. Susceptibility of zero community transmission regimes to new variants of SARS-CoV-2: a modelling study of Queensland. medRxiv. 2021 Jul 8;2021.06.08.21258599.
11. Kim D, Keskinocak P, Pekgün P, Yildirim I. The Balancing Role of Distribution Speed against Varying Efficacy Levels of COVID-19 Vaccines under Variants. medRxiv. 2021 Apr 13;2021.04.09.21255217.
12. Braun P, Braun J, Woodcock BG. COVID-19: Effect-modelling of vaccination in Germany with regard to the mutant strain B.1.1.7 and occupancy of ICU facilities. Int J Clin Pharmacol Ther. 2021 Jul 1;59(07):487–95.
13. Mancuso M, Eikenberry SE, Gumel AB. Will Vaccine-derived Protective Immunity Curtail COVID-19 Variants in the US? medRxiv. 2021 Jul 13;2021.06.30.21259782.
14. Moghadas SM, Sah P, Fitzpatrick MC, Shoukat A, Pandey A, Vilches TN, et al. COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States. medRxiv. 2021 Jul 8;2021.07.07.21260156.
15. Berec L, Levínský R, Weiner J, Šmíd M, Neruda R, Vidnerová P, et al. Importance of epidemic severity and vaccine mode of action and availability for delaying the second vaccine dose. medRxiv. 2021 Jul 5;2021.06.30.21259752.
16. Quinonez E, Vahed M, Hashemi Shahraki A, Mirsaeidi M. Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. Viruses. 2021 May;13(5):930.
17. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel. Cell Rep Med. 2021 May 18;2(5):100264.

18. Victora C, Castro MC, Gurzenda S, Barros AJD. Estimating the early impact of immunization against COVID-19 on deaths among elderly people in Brazil: analyses of secondary data on vaccine coverage and mortality. medRxiv. 2021 Apr 30;2021.04.27.21256187.
19. Giordano G, Colaneri M, Di Filippo A, Blanchini F, Bolzern P, De Nicolao G, et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nat Med. 2021 Apr 16;1–6.
20. Pageaud S, Ponthus N, Gauchon R, Pothier C, Rigotti C, Eyraud-Loisel A, et al. Adapting French COVID-19 vaccination campaign duration to variant dissemination. medRxiv. 2021 Mar 20;2021.03.17.21253739.
21. Sachak-Patwa R, Byrne H, Dyson L, Thompson R. The risk of SARS-CoV-2 outbreaks in low prevalence settings following the removal of travel restrictions [Internet]. Research Square. 2021 [cited 2021 Jul 27]. Available from: <https://www.researchsquare.com/article/rs-547702/v1>
22. Betti M, Bragazzi N, Heffernan J, Kong J, Raad A. Could a New COVID-19 Mutant Strain Undermine Vaccination Efforts? A Mathematical Modelling Approach for Estimating the Spread of B.1.1.7 Using Ontario, Canada, as a Case Study. Vaccines. 2021 Jun;9(6):592.
23. Borchering RK. Modeling of Future COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Rates and Nonpharmaceutical Intervention Scenarios — United States, April–September 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Jul 27];70. Available from: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7019e3.htm>
24. Conn H, Taylor R, Willis MJ, Wright A, Bramfitt V. Mechanistic model calibration and the dynamics of the COVID-19 epidemic in the UK (the past, the present and the future). medRxiv. 2021 May 22;2021.05.18.21257384.
25. Jayasundara P, Peariasamy KM, Law KB, Rahim KNKA, Lee SW, Ghazali IMM, et al. Sustaining effective COVID-19 control in Malaysia through large-scale vaccination. medRxiv. 2021 Jul 7;2021.07.05.21259999.
26. Dimeglio C, Milhes M, Loubes J-M, Ranger N, Mansuy J-M, Trémeaux P, et al. Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2. Viruses. 2021 May;13(5):898.
27. Zou Z, Fairley CK, Shen M, Scott N, Xu X, Li Z, et al. Critical timing for triggering public health interventions to prevent COVID-19 resurgence: a mathematical modelling study. medRxiv. 2021 Jul 7;2021.07.06.21260055.
28. Domenico LD, Sabbatini CE, Pullano G, Lévy-Bruhl D, Colizza V. Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France. medRxiv. 2021 Mar 10;2021.02.14.21251708.

29. Bauer S, Contreras S, Dehning J, Linden M, Iftekhar E, Mohr SB, et al. Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves. 2021 Jul. Report No.: arXiv:2103.06228v4.
30. Turner D, Égert B, Guillemette Y, Botev J. The tortoise and the hare: The race between vaccine rollout and new COVID variants. 2021 Jun 11 [cited 2021 Jul 27]; Available from: https://www.oecd-ilibrary.org/economics/the-tortoise-and-the-hare-the-race-between-vaccine-rollout-and-new-covid-variants_4098409d-en
31. Yang HM, Junior LPL, Castro FFM, Yang AC. Quarantine, relaxation and mutation explaining the CoViD-19 epidemic in São Paulo State (Brazil). medRxiv. 2021 Apr 15;2021.04.12.21255325.
32. Meister T, Fortmann J, Todt D, Heinen N, Ludwig A, Brüggemann Y, et al. Comparable environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351. 2021.
33. Gurbaxani BM, Hill AN, Paul P, Prasad PV, Slayton RB. Evaluation of Different Types of Face Masks to Limit the Spread of SARS-CoV-2 – A Modeling Study. medRxiv. 2021 Apr 27;2021.04.21.21255889.
34. Chen C, Packer S, Turner C, Anderson C, Hughes G, Edeghere O, et al. Using Genomic Concordance to Estimate COVID-19 Transmission Risk Across Different Community Settings in England 2020/21. Prepr Lancet [Internet]. 2021 Jun 15 [cited 2021 Jul 27]; Available from: <https://papers.ssrn.com/abstract=3867682>
35. Borges V, Sousa C, Menezes L, Gonçalves AM, Picão M, Almeida JP, et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2021 Mar;26(10).
36. Piantham C, Ito K. Estimating the increased transmissibility of the B.1.1.7 strain over previously circulating strains in England using frequencies of GISAID sequences and the distribution of serial intervals. medRxiv. 2021 Mar 30;2021.03.17.21253775.
37. Neuberger F, Grgic M, Diefenbacher S, Spensberger F, Lehfeld A-S, Buchholz U, et al. COVID-19 infections in day care centres in Germany: Social and organisational determinants of infections in children and staff in the second and third wave of the pandemic. medRxiv. 2021 Jul 3;2021.06.07.21257958.
38. Van Egeren D, Stoddard M, Novodhodko A, Rogers M, Joseph-McCarthy D, Zetter B, et al. The specter of Manaus: the risks of a rapid return to pre-pandemic conditions after COVID-19 vaccine rollout. 2021 May.
39. Lane CR, Sherry NL, Porter AF, Duchene S, Horan K, Andersson P, et al. Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study. Lancet Public Health [Internet]. 2021 Jul 9

- [cited 2021 Jul 27];0(0). Available from:
[https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(21\)00133-X/abstract](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00133-X/abstract)
40. Kühn MJ, Abele D, Binder S, Rack K, Klitz M, Kleinert J, et al. Regional opening strategies with commuter testing and containment of new SARS-CoV-2 variants. medRxiv. 2021 Apr 26;2021.04.23.21255995.
 41. Aubry M, Teiti I, Teissier A, Richard V, Mariteragi-Helle T, Chung K, et al. Self-collection and pooling of samples as resources-saving strategies for RT-PCR-based SARS-CoV-2 surveillance, the example of travelers in French Polynesia. medRxiv. 2021 Jun 21;2021.06.17.21254195.
 42. Quilty BJ, Russell TW, Clifford S, Flasche S, Pickering S, Neil SJ, et al. Quarantine and testing strategies to reduce transmission risk from imported SARS-CoV-2 infections: a global modelling study [Internet]. *Epidemiology*; 2021 Jun [cited 2021 Jul 29]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.06.11.21258735>
 43. Adamoski D, Oliveira JC de, Bonatto AC, Wassem R, Nogueira MB, Raboni SM, et al. Large-scale screening of asymptomatic for SARS-CoV-2 variants of concern and rapid P.1 takeover, Curitiba, Brazil. medRxiv. 2021 Jun 21;2021.06.18.21258649.
 44. Du Z, Wang L, Bai Y, Wang X, Pandey A, Chinazzi M, et al. Cost Effective Proactive Testing Strategies During COVID-19 Mass Vaccination: A Modelling Study. Prepr Lancet [Internet]. 2021 Jul 1 [cited 2021 Jul 27]; Available from: <https://papers.ssrn.com/abstract=3878074>
 45. Bilinski A, Ciaranello A, Fitzpatrick MC, Giardina J, Shah M, Salomon JA, et al. SARS-CoV-2 testing strategies to contain school-associated transmission: model-based analysis of impact and cost of diagnostic testing, screening, and surveillance. 2021 Aug.
 46. Chudasama DY, Flannagan J, Collin SM, Charlett A, Twohig KA, Lamagni T, et al. Household clustering of SARS-CoV-2 variant of concern B.1.1.7 (VOC-202012–01) in England. *J Infect* [Internet]. 2021 Apr 29 [cited 2021 May 26];0(0). Available from: [https://www.journalofinfection.com/article/S0163-4453\(21\)00216-4/abstract](https://www.journalofinfection.com/article/S0163-4453(21)00216-4/abstract)
 47. Buchan SA, Tibebe S, Daneman N, Whelan M, Vanniyasingam T, Murti M, et al. Increased household secondary attacks rates with Variant of Concern SARS-CoV-2 index cases. medRxiv. 2021 Apr 5;2021.03.31.21254502.
 48. Wells CR, Townsend JP, Pandey A, Fitzpatrick MC, Crystal WS, Moghadas SM, et al. Quarantine and testing strategies for safe pandemic travel [Internet]. *Epidemiology*; 2021 Apr [cited 2021 May 26]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2021.04.25.21256082>
 49. Linka K, Peirlinck M, Schäfer A, Tikenogullari OZ, Goriely A, Kuhl E. Effects of B.1.1.7 and B.1.351 on COVID-19 dynamics. A campus reopening study. medRxiv. 2021 Apr 27;2021.04.22.21255954.

50. Maison DP, Cleveland SB, Nerurkar VR. Genomic Analysis of SARS-CoV-2 Variants of Concern Circulating in Hawai'i to Facilitate Public-Health Policies [Internet]. Research Square. 2021 [cited 2021 Jul 27]. Available from: <https://www.researchsquare.com/article/rs-378702/v2>
51. Zimmerman RA, Cadegiani FA, Pereira E Costa RA, Goren A, Campello de Souza B. Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants. *Cureus*. 2021 Mar 11;13(3):e13819.
52. Bosetti P, Kiem CT, Andronico A, Paireau J, Bruhl DL, Lina B, et al. A race between SARS-CoV-2 variants and vaccination: The case of the B.1.1.7 variant in France [Internet]. 2021 [cited 2021 May 26]. Available from: <https://hal-pasteur.archives-ouvertes.fr/pasteur-03149525>
53. Ahn H-S, Silberholz J, Song X, Wu X. Optimal COVID-19 Containment Strategies: Evidence Across Multiple Mathematical Models [Internet]. Rochester, NY: Social Science Research Network; 2021 Apr [cited 2021 May 26]. Report No.: ID 3834668. Available from: <https://papers.ssrn.com/abstract=3834668>
54. Scherbina A. Would the United States Benefit from a COVID Lockdown? Reassessing the Situation. SSRN [Internet]. 2021 Feb 20 [cited 2021 Apr 26]; Available from: <https://papers.ssrn.com/abstract=3789690>
55. Salvatore M, Bhattacharyya R, Purkayastha S, Zimmermann L, Ray D, Hazra A, et al. Resurgence of SARS-CoV-2 in India: Potential role of the B.1.617.2 (Delta) variant and delayed interventions. 2021 Jun. Report No.: 10.1101/2021.06.23.21259405.
56. Loenenbach A, Markus I, Lehfeld A-S, Heiden M an der, Haas W, Kiegele M, et al. SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021. *Eurosurveillance*. 2021 May 27;26(21):2100433.
57. Nielsen BF, Eilersen A, Simonsen L, Sneppen K. Lockdowns exert selection pressure on overdispersion of SARS-CoV-2 variants. *medRxiv*. 2021 Jul 6;2021.06.30.21259771.
58. Bowie C. Modelling the effect of an improved trace and isolate system in the wake of a highly transmissible Covid-19 variant with potential vaccine escape. *medRxiv*. 2021 Jun 10;2021.06.07.21258451.